{"filing":{"accession_number":"0001140361-26-023698","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"ef20075449_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126023698/ef20075449_8k.htm"},"events":[{"id":7413,"run_id":6513,"accession_number":"0001140361-26-023698","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and subsequently regained compliance by June 2, 2026. This is a classic delisting risk disclosure—the company faced potential delisting but has now resolved the non-compliance. The resolution of the matter is material to investors as it confirms the company's continued listing status on Nasdaq.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-02","submitted_at":null,"items":[{"id":3506,"accession_number":"0001140361-26-023698","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and subsequently regained compliance by June 2, 2026. This is a classic delisting risk disclosure—the company faced potential delisting but has now resolved the non-compliance. The resolution of the matter is material to investors as it confirms the company's continued listing status on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:34.831811+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3506,"accession_number":"0001140361-26-023698","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and subsequently regained compliance by June 2, 2026. This is a classic delisting risk disclosure—the company faced potential delisting but has now resolved the non-compliance. The resolution of the matter is material to investors as it confirms the company's continued listing status on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:12:34.831811+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-02"}]}